Bristol-Myers Squibb Company Ce (CELG-RI)
Valuation Overview•Is Bristol-Myers Squibb Company Ce Overvalued or Undervalued?
Popular:
Above average — solid fundamentals with minor weakness
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $1.42 | $1.58 | +11.3% | ||
| Q1'26 | $1.23 | $1.26 | +2.4% | ||
| Q4'25 | $1.52 | $1.08 | -28.9% | ||
| Q3'25 | $1.09 | — | — | ||
| Q2'25 | $1.49 | $1.21 | -18.8% | ||
| Q3'23 | — | — | — | ||
| Q2'23 | — | — | — | ||
| Q1'23 | — | — | — |
Total return, benchmark alpha, and annual history in one section.
3Y, 5Y, and 10Y use CAGR when available.
| Period | Return | vs S&P | Dividends |
|---|---|---|---|
| YTD | +53.0% | +45.6% | — |
| 1Y | +278.0% | +246.7% | — |
| 3YCAGR | +5.0% | -18.8% | +17.8% |
| 5YCAGR | +8.6% | -4.2% | +80.4% |
| 10YCAGR | +13.0% | -0.8% | — |
Year-by-year total return versus SPY, including dividend contribution.
| Year | Stock Return | SPY Return | Alpha | Dividends |
|---|---|---|---|---|
| 2026YTD | +35.9% | +0.4% | +35.5% | — |
| 2025 | +27.0% | +16.6% | +10.4% | — |
| 2024 | -11.1% | +24.0% | -35.1% | +25.7% |
| 2023Worst | -26.2% | +24.8% | -51.0% | — |
| 2022Best | +43.7% | -19.9% | +63.6% | +67.5% |
Based on our multi-model analysis of Bristol-Myers Squibb Company Ce (CELG-RI) at $0.11: Fundamental quality score: 69/100 (moderate). This is a quantitative summary combining DCF intrinsic value, peer-based relative valuation, quality scoring, and analyst consensus — not a buy/sell recommendation. Always consult a qualified financial advisor before investing.
Fair value data is not yet available for CELG-RI.
Bristol-Myers Squibb Company Ce's financial health as measured by our composite scoring: Overall quality score: 69/100. Piotroski F-Score: 8/9 (strong fundamentals). Altman Z-Score: 0.8 (distress zone — elevated risk). Return on invested capital: 19.8%. Cash conversion (OCF/NI): 2.01x (earnings are cash-backed). The quality score blends profitability (ROIC, ROE, margins), solvency (leverage, coverage, Z-Score), and growth trajectory into a single 0–100 framework updated end-of-day.
Bristol-Myers Squibb Company Ce's performance profile: 1-year total return: +278.0%. 1-year alpha vs S&P 500: +246.7% (outperforming the benchmark). 5-year CAGR: +8.6%. Maximum drawdown (1Y): -64.3%. Relative Strength rating: 92/99 (strong momentum). Beta: -0.37 (less volatile than the market). Total returns include reinvested dividends. Alpha is calculated against the S&P 500 Total Return Index over matching periods.
Current dividend yield: 100.0%. Annual dividend per share: $2.47. Payout ratio: 72% (moderate). Consecutive years of growth: 6 (growing). 5-year dividend CAGR: +6.5%. Total shareholder yield (dividends + buybacks): 100.0%.
Wall Street's outlook on Bristol-Myers Squibb Company Ce: Earnings beat rate: 50% with a 2-quarter consecutive beat streak. Forward P/E: 0.0x. Analyst estimates are blended into our proprietary model with weight based on coverage depth and historical accuracy. We track estimate revisions, beat rates, and grade changes daily.
Key risks identified for Bristol-Myers Squibb Company Ce: Drawdown risk: The stock experienced a -64.3% max drawdown in the past year. Solvency risk: Altman Z-Score (0.8) is in the distress zone, indicating elevated bankruptcy risk. Note: This model does not capture regulatory changes, management decisions, competitive disruption, or geopolitical events. Macro and qualitative risks remain material and should be assessed independently.
No. This overview dashboard aggregates data from our DCF intrinsic value model, relative peer multiples model, proprietary estimates engine, and third-party analyst consensus feeds. It is strictly for educational and informational purposes. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, quality scores, and signals are automated quantitative computations and should not be construed as investment recommendations. Consult a qualified, licensed financial advisor before making any investment decisions. Past model performance does not guarantee future results.